Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14294 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Sara Redondo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Barcelona, Spain. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Methotrexate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Catalan Government, Barcelona, Spain, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Objective
This retrospective single center study aims to describe changes in the severity and organ‐specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.
Methods
Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA‐matched or 1‐allele mismatched related or unrelated donors. Fifty‐eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort‐1), 87 (38%) tacrolimus plus sirolimus (Cohort‐2), and 81 (36%) post‐transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort‐3).
Results
The incidence of grade II‐IV aGvHD was 69% vs. 41.4% vs. 27.2%; p < .01. The most significant reduction with PTCy was observed in both stage 3–4 skin and lower gastrointestinal (GI) involvement ( p < .01). The incidence of moderate‐to‐severe cGvHD at 12 months was 34.5% vs. 34.5% vs. 6.2%; p < .01. Moderate‐to‐severe skin and GI cGvHD was less common after PTCy ( p < .01). The 1‐year GvHD‐free/relapse‐free survival was higher with PTCy ( p < .01).
Conclusions
Our study indicates that PTCy‐based GvHD prophylaxis reduces the frequency and severity of both acute and chronic GvHD, with a notable decrease in severe GI and cutaneous manifestations. The higher GRFS may result in lower GvHD‐related mortality, leading to an improved quality of life among survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Barcelona, Spain.
- Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Sara Redondo, Irene García-Cadenas, Albert Esquirol
Förderung
- Catalan Government, Barcelona, Spain
- Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain
- Instituto de Salud Carlos III
Zitieren
APA
Redondo, S., García-Cadenas, I., Esquirol, A., Portos, J. M., Iranzo, E., Arguello-Tomas, M., Saavedra, S., Oñate, G., Caballero, A. C., Garrido, A., López, J., Muntañola, A., Paviglianiti, A., Miqueleiz, S., Sierra, J., Briones, J., & Martino, R. (2024). Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14294
Vancouver
Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, et al. Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation. European Journal of Haematology. 2024. doi:10.1111/ejh.14294
BibTeX
@article{Redondo2024,
author = {Redondo, Sara and García-Cadenas, Irene and Esquirol, Albert and Portos, J M and Iranzo, Eva and Arguello-Tomas, Miguel and Saavedra, Silvana and Oñate, Guadalupe and Caballero, Ana-Carolina and Garrido, Ana and López, Jordi and Muntañola, Ana and Paviglianiti, Annalisa and Miqueleiz, Sara and Sierra, Jorge and Briones, Javier and Martino, Rodrigo},
title = {Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14294}
}
EUVIMED